EP1312607A1 - Dithiocarbamat Derivate und deren Verwendung als bakterientötendes Mittel - Google Patents

Dithiocarbamat Derivate und deren Verwendung als bakterientötendes Mittel Download PDF

Info

Publication number: EP1312607A1
Authority: EP; European Patent Office
Prior art keywords: nitropyrimidine; dinitro; formula; nitro; pyrimidine
Prior art date: 2001-11-17
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Withdrawn

Application number

EP01127296A

Other languages

English (en)

French (fr)

Inventor

Vadim Dr. Makarov

Ute Dr. Möllmann

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

MEDAC GmbH

Original Assignee

MEDAC GmbH

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2001-11-17

Filing date

2001-11-17

Publication date

2003-05-21

2001-11-17 Application filed by MEDAC GmbH filed Critical MEDAC GmbH

2001-11-17 Priority to EP01127296A priority Critical patent/EP1312607A1/de

2002-11-18 Priority to PCT/EP2002/012826 priority patent/WO2003042186A1/en

2002-11-18 Priority to EP02787700A priority patent/EP1448533A1/de

2002-11-18 Priority to US10/495,651 priority patent/US20050032822A1/en

2002-11-18 Priority to CNB028271815A priority patent/CN1310892C/zh

2002-11-18 Priority to APAP/P/2004/003064A priority patent/AP1684A/en

2003-05-21 Publication of EP1312607A1 publication Critical patent/EP1312607A1/de

2004-06-11 Priority to ZA200404665A priority patent/ZA200404665B/en

2008-06-06 Priority to US12/155,604 priority patent/US20080255166A1/en

Status Withdrawn legal-status Critical Current

Links

239000003242 anti bacterial agent Substances 0.000 title description 2
150000004659 dithiocarbamates Chemical class 0.000 title description 2
150000001875 compounds Chemical class 0.000 claims abstract description 32
241000124008 Mammalia Species 0.000 claims abstract description 4
238000011321 prophylaxis Methods 0.000 claims abstract 2
230000001225 therapeutic effect Effects 0.000 claims abstract 2
-1 aliphatic radical Chemical class 0.000 claims description 20
238000000034 method Methods 0.000 claims description 17
229920006395 saturated elastomer Polymers 0.000 claims description 16
125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 12
125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 12
150000003254 radicals Chemical class 0.000 claims description 10
125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims description 9
229910052736 halogen Inorganic materials 0.000 claims description 6
150000002367 halogens Chemical class 0.000 claims description 6
JUJWROOIHBZHMG-UHFFFAOYSA-N pyridine Substances C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 claims description 6
125000004432 carbon atom Chemical group C* 0.000 claims description 4
208000035143 Bacterial infection Diseases 0.000 claims description 3
208000022362 bacterial infectious disease Diseases 0.000 claims description 3
125000000753 cycloalkyl group Chemical group 0.000 claims description 3
125000004573 morpholin-4-yl group Chemical group N1(CCOCC1)* 0.000 claims description 3
125000001624 naphthyl group Chemical group 0.000 claims description 3
UHOVQNZJYSORNB-UHFFFAOYSA-N benzene Substances C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 claims description 2
230000007717 exclusion Effects 0.000 claims description 2
239000008194 pharmaceutical composition Substances 0.000 claims description 2
JFDZBHWFFUWGJE-UHFFFAOYSA-N benzonitrile Substances N#CC1=CC=CC=C1 JFDZBHWFFUWGJE-UHFFFAOYSA-N 0.000 claims 1
201000008827 tuberculosis Diseases 0.000 abstract description 12
241000295644 Staphylococcaceae Species 0.000 abstract description 7
230000000844 anti-bacterial effect Effects 0.000 abstract description 7
208000035473 Communicable disease Diseases 0.000 abstract description 4
201000010099 disease Diseases 0.000 abstract description 4
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 4
241000894006 Bacteria Species 0.000 abstract description 3
241001465754 Metazoa Species 0.000 abstract description 3
241000236488 Lepra Species 0.000 abstract description 2
206010024229 Leprosy Diseases 0.000 abstract description 2
239000007787 solid Substances 0.000 description 31
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 24
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 11
238000002425 crystallisation Methods 0.000 description 8
230000008025 crystallization Effects 0.000 description 8
239000003814 drug Substances 0.000 description 8
239000011541 reaction mixture Substances 0.000 description 8
229940079593 drug Drugs 0.000 description 7
230000002401 inhibitory effect Effects 0.000 description 7
CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 6
XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 6
239000000203 mixture Substances 0.000 description 6
230000000694 effects Effects 0.000 description 4
239000002609 medium Substances 0.000 description 4
239000000243 solution Substances 0.000 description 4
239000000725 suspension Substances 0.000 description 4
GUDFEGXIJXTNJG-UHFFFAOYSA-N 2-chloro-3,5-dinitrobenzamide Chemical compound NC(=O)C1=CC([N+]([O-])=O)=CC([N+]([O-])=O)=C1Cl GUDFEGXIJXTNJG-UHFFFAOYSA-N 0.000 description 3
GXBZQHWSOAJTLZ-UHFFFAOYSA-N 2-chloro-3,5-dinitrobenzonitrile Chemical compound [O-][N+](=O)C1=CC(C#N)=C(Cl)C([N+]([O-])=O)=C1 GXBZQHWSOAJTLZ-UHFFFAOYSA-N 0.000 description 3
OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
239000007788 liquid Substances 0.000 description 3
239000011734 sodium Substances 0.000 description 3
229910052708 sodium Inorganic materials 0.000 description 3
NQVBYQPOGVWUPK-UHFFFAOYSA-M sodium;n,n-dimethylcarbamodithioate;dihydrate Chemical compound O.O.[Na+].CN(C)C([S-])=S NQVBYQPOGVWUPK-UHFFFAOYSA-M 0.000 description 3
0 CCCN(CCC)C(SC(CCC*CCCC1)=C1[N+]([O-])=O)=S Chemical compound CCCN(CCC)C(SC(CCC*CCCC1)=C1[N+]([O-])=O)=S 0.000 description 2
KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
241001646725 Mycobacterium tuberculosis H37Rv Species 0.000 description 2
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
230000000845 anti-microbial effect Effects 0.000 description 2
239000003610 charcoal Substances 0.000 description 2
AEUTYOVWOVBAKS-UWVGGRQHSA-N ethambutol Chemical compound CC[C@@H](CO)NCCN[C@@H](CC)CO AEUTYOVWOVBAKS-UWVGGRQHSA-N 0.000 description 2
208000015181 infectious disease Diseases 0.000 description 2
239000006379 löwenstein-jensen medium Substances 0.000 description 2
239000013049 sediment Substances 0.000 description 2
WWGXHTXOZKVJDN-UHFFFAOYSA-M sodium;n,n-diethylcarbamodithioate;trihydrate Chemical compound O.O.O.[Na+].CCN(CC)C([S-])=S WWGXHTXOZKVJDN-UHFFFAOYSA-M 0.000 description 2
UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
HEEACTTWORLLPM-UHFFFAOYSA-N 2-(1h-imidazol-5-yl)ethanol Chemical compound OCCC1=CNC=N1 HEEACTTWORLLPM-UHFFFAOYSA-N 0.000 description 1
QLHVJBXAQWPEDI-UHFFFAOYSA-N 2-chloro-3,5-dinitropyridine Chemical compound [O-][N+](=O)C1=CN=C(Cl)C([N+]([O-])=O)=C1 QLHVJBXAQWPEDI-UHFFFAOYSA-N 0.000 description 1
YZTJXHWQWCLEJX-UHFFFAOYSA-N 4-chloro-6-methoxy-5-nitropyrimidine Chemical compound COC1=NC=NC(Cl)=C1[N+]([O-])=O YZTJXHWQWCLEJX-UHFFFAOYSA-N 0.000 description 1
UOIJIZBXRZREBE-UHFFFAOYSA-N 6-chloro-5-nitro-n-propan-2-ylpyrimidin-4-amine Chemical compound CC(C)NC1=NC=NC(Cl)=C1[N+]([O-])=O UOIJIZBXRZREBE-UHFFFAOYSA-N 0.000 description 1
HJCNZFOBWVEBNC-UHFFFAOYSA-N 6-chloro-n-methyl-5-nitropyrimidin-4-amine Chemical compound CNC1=NC=NC(Cl)=C1[N+]([O-])=O HJCNZFOBWVEBNC-UHFFFAOYSA-N 0.000 description 1
206010061822 Drug intolerance Diseases 0.000 description 1
206010059866 Drug resistance Diseases 0.000 description 1
206010062207 Mycobacterial infection Diseases 0.000 description 1
241000186365 Mycobacterium fortuitum Species 0.000 description 1
241000187480 Mycobacterium smegmatis Species 0.000 description 1
108700035964 Mycobacterium tuberculosis HsaD Proteins 0.000 description 1
241000187644 Mycobacterium vaccae Species 0.000 description 1
241000144944 Mylossoma aureum Species 0.000 description 1
239000007832 Na2SO4 Substances 0.000 description 1
101100062394 Picea mariana DAD1 gene Proteins 0.000 description 1
PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 1
NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
238000002441 X-ray diffraction Methods 0.000 description 1
KGTSLTYUUFWZNW-PPJQWWMSSA-N [(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate pyridine-4-carbohydrazide Chemical compound NNC(=O)c1ccncc1.CO[C@H]1\C=C\O[C@@]2(C)Oc3c(C2=O)c2c(O)c(\C=N\N4CCN(C)CC4)c(NC(=O)\C(C)=C/C=C/[C@H](C)[C@H](O)[C@@H](C)[C@@H](O)[C@@H](C)[C@H](OC(C)=O)[C@@H]1C)c(O)c2c(O)c3C KGTSLTYUUFWZNW-PPJQWWMSSA-N 0.000 description 1
208000036981 active tuberculosis Diseases 0.000 description 1
125000003342 alkenyl group Chemical group 0.000 description 1
125000000217 alkyl group Chemical group 0.000 description 1
238000004458 analytical method Methods 0.000 description 1
238000009635 antibiotic susceptibility testing Methods 0.000 description 1
239000007900 aqueous suspension Substances 0.000 description 1
QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
230000003385 bacteriostatic effect Effects 0.000 description 1
229940054066 benzamide antipsychotics Drugs 0.000 description 1
230000015572 biosynthetic process Effects 0.000 description 1
230000037396 body weight Effects 0.000 description 1
239000012267 brine Substances 0.000 description 1
239000004490 capsule suspension Substances 0.000 description 1
239000003795 chemical substances by application Substances 0.000 description 1
230000034994 death Effects 0.000 description 1
231100000517 death Toxicity 0.000 description 1
239000012895 dilution Substances 0.000 description 1
238000010790 dilution Methods 0.000 description 1
229960000285 ethambutol Drugs 0.000 description 1
239000000284 extract Substances 0.000 description 1
244000000059 gram-positive pathogen Species 0.000 description 1
238000011534 incubation Methods 0.000 description 1
239000002054 inoculum Substances 0.000 description 1
238000010255 intramuscular injection Methods 0.000 description 1
239000007927 intramuscular injection Substances 0.000 description 1
238000010253 intravenous injection Methods 0.000 description 1
238000001819 mass spectrum Methods 0.000 description 1
230000007246 mechanism Effects 0.000 description 1
230000000813 microbial effect Effects 0.000 description 1
238000005142 microbroth dilution method Methods 0.000 description 1
201000009671 multidrug-resistant tuberculosis Diseases 0.000 description 1
208000027531 mycobacterial infectious disease Diseases 0.000 description 1
XJZVSYRZTQQOHZ-UHFFFAOYSA-N n-[5-[(2-methoxy-5-nitrophenyl)methylsulfanyl]-1,3,4-thiadiazol-2-yl]acetamide Chemical compound COC1=CC=C([N+]([O-])=O)C=C1CSC1=NN=C(NC(C)=O)S1 XJZVSYRZTQQOHZ-UHFFFAOYSA-N 0.000 description 1
239000002547 new drug Substances 0.000 description 1
238000000655 nuclear magnetic resonance spectrum Methods 0.000 description 1
229910052760 oxygen Inorganic materials 0.000 description 1
239000001301 oxygen Substances 0.000 description 1
238000007911 parenteral administration Methods 0.000 description 1
239000000546 pharmaceutical excipient Substances 0.000 description 1
125000004193 piperazinyl group Chemical group 0.000 description 1
239000011780 sodium chloride Substances 0.000 description 1
229910052938 sodium sulfate Inorganic materials 0.000 description 1
HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 1
239000007858 starting material Substances 0.000 description 1
229960005322 streptomycin Drugs 0.000 description 1
238000010254 subcutaneous injection Methods 0.000 description 1
239000007929 subcutaneous injection Substances 0.000 description 1
125000001424 substituent group Chemical group 0.000 description 1
239000006228 supernatant Substances 0.000 description 1
238000003786 synthesis reaction Methods 0.000 description 1
239000003826 tablet Substances 0.000 description 1
238000002560 therapeutic procedure Methods 0.000 description 1
238000011200 topical administration Methods 0.000 description 1
230000000699 topical effect Effects 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/56—One oxygen atom and one sulfur atom
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A61P31/06—Antibacterial agents for tuberculosis
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/62—Oxygen or sulfur atoms
- C07D213/70—Sulfur atoms
- C07D213/71—Sulfur atoms to which a second hetero atom is attached
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/47—One nitrogen atom and one oxygen or sulfur atom, e.g. cytosine

Definitions

the invention relates furthermore to a compound of the formula I for use in a method for the treatment of bacterial infections in mammals.
Preferred compounds of the formula I for use in such method are those specifically listed above plus additionally 4-methylamino-6-diethyldithiocarbamoyl-5-nitropyrimidine.

Landscapes

Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Health & Medical Sciences (AREA)
Communicable Diseases (AREA)
Oncology (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Pulmonology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

EP01127296A 2001-11-17 2001-11-17 Dithiocarbamat Derivate und deren Verwendung als bakterientötendes Mittel Withdrawn EP1312607A1 (de)

Priority Applications (8)

Application Number	Priority Date	Filing Date	Title
EP01127296A EP1312607A1 (de)	2001-11-17	2001-11-17	Dithiocarbamat Derivate und deren Verwendung als bakterientötendes Mittel
PCT/EP2002/012826 WO2003042186A1 (en)	2001-11-17	2002-11-18	Dithiocarbamate derivatives and their use as antibacterial agents
EP02787700A EP1448533A1 (de)	2001-11-17	2002-11-18	Dithiocarbamatderivate und deren verwendung als antibacterielle mittel
US10/495,651 US20050032822A1 (en)	2001-11-17	2002-11-18	Dithiocarbamate derivatives and their use as antibacterial agents
CNB028271815A CN1310892C (zh)	2001-11-17	2002-11-18	二硫代氨基甲酸酯衍生物及其作为抗菌剂的应用
APAP/P/2004/003064A AP1684A (en)	2001-11-17	2002-11-18	Dithiocarbamate derivatives and their use as antibacterial agents.
ZA200404665A ZA200404665B (en)	2001-11-17	2004-06-11	Dithiocarbamate derivatives and their use as antibacterial agents.
US12/155,604 US20080255166A1 (en)	2001-11-17	2008-06-06	Dithiocarbamate derivatives and their use as antibacterial agents

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
EP01127296A EP1312607A1 (de)	2001-11-17	2001-11-17	Dithiocarbamat Derivate und deren Verwendung als bakterientötendes Mittel

Publications (1)

Publication Number	Publication Date
EP1312607A1 true EP1312607A1 (de)	2003-05-21

Family

ID=8179261

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
EP01127296A Withdrawn EP1312607A1 (de)	2001-11-17	2001-11-17	Dithiocarbamat Derivate und deren Verwendung als bakterientötendes Mittel
EP02787700A Withdrawn EP1448533A1 (de)	2001-11-17	2002-11-18	Dithiocarbamatderivate und deren verwendung als antibacterielle mittel

Family Applications After (1)

Application Number	Title	Priority Date	Filing Date
EP02787700A Withdrawn EP1448533A1 (de)	2001-11-17	2002-11-18	Dithiocarbamatderivate und deren verwendung als antibacterielle mittel

Country Status (6)

Country	Link
US (2)	US20050032822A1 (de)
EP (2)	EP1312607A1 (de)
CN (1)	CN1310892C (de)
AP (1)	AP1684A (de)
WO (1)	WO2003042186A1 (de)
ZA (1)	ZA200404665B (de)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CN101472922B (zh)	2006-05-24	2012-05-30	e.V.汉斯-诺尔-研究院（HKI）莱布尼茨天然产物研究和感染生物学研究所	苯并噻嗪酮衍生物及其作为抗菌剂的应用

Citations (2)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP0036841A1 (de) *	1980-03-26	1981-09-30	Ciba-Geigy Ag	Verfahren zur Herstellung von 1,3-Benzodithiolderivaten
US4406902A (en) *	1980-09-17	1983-09-27	Merck & Co., Inc.	Dipeptidase inhibitors

2001
- 2001-11-17 EP EP01127296A patent/EP1312607A1/de not_active Withdrawn
2002
- 2002-11-18 US US10/495,651 patent/US20050032822A1/en not_active Abandoned
- 2002-11-18 WO PCT/EP2002/012826 patent/WO2003042186A1/en not_active Ceased
- 2002-11-18 CN CNB028271815A patent/CN1310892C/zh not_active Expired - Fee Related
- 2002-11-18 EP EP02787700A patent/EP1448533A1/de not_active Withdrawn
- 2002-11-18 AP APAP/P/2004/003064A patent/AP1684A/en active
2004
- 2004-06-11 ZA ZA200404665A patent/ZA200404665B/en unknown
2008
- 2008-06-06 US US12/155,604 patent/US20080255166A1/en not_active Abandoned

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP0036841A1 (de) *	1980-03-26	1981-09-30	Ciba-Geigy Ag	Verfahren zur Herstellung von 1,3-Benzodithiolderivaten
US4406902A (en) *	1980-09-17	1983-09-27	Merck & Co., Inc.	Dipeptidase inhibitors

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
CHEMICAL ABSTRACTS, vol. 123, no. 28, 1995, Columbus, Ohio, US; abstract no. 143795g, MAKAROV,V.: "INVESTIGATION OF BISHETEROARYL DERIVATIVES OF PIPERAZINE A. ITS ANALOGS." page 1265; XP002195908 *
KHALID RASHEED: "THERMAL DECOMPOSITION OF DINITROPYRIDYL AND DINITROTHIENYL DITHIOCARBAMATES", JOURNAL OF HETEROCYCLIC CHEMISTRY., vol. 18, no. 8, December 1981 (1981-12-01), HETEROCORPORATION. PROVO., US, pages 1581 - 5, XP002195907, ISSN: 0022-152X *
KHIM. GETEROTSIKL. SOEDIN, vol. 2, 1995, RUSSIA, pages 208 - 10 *
PREM DUREJA: "SYNTHESIS A. FUNGITOXICITY OF HALOGENONITROPHENYL ESTERS OF N-(PRPO...)DITHIOFORMIC ACIDS.", J. INDIAN CHEM. SOC., vol. 57, no. 10, 1980, CALCUTTA, pages 1017 - 19, XP001064804 *

Also Published As

Publication number	Publication date
CN1615301A (zh)	2005-05-11
AP1684A (en)	2006-11-29
ZA200404665B (en)	2004-10-12
US20080255166A1 (en)	2008-10-16
CN1310892C (zh)	2007-04-18
EP1448533A1 (de)	2004-08-25
AP2004003064A0 (en)	2004-06-30
WO2003042186A1 (en)	2003-05-22
US20050032822A1 (en)	2005-02-10

Legal Events

Date	Code	Title	Description
2003-04-04	PUAI	Public reference made under article 153(3) epc to a published international application that has entered the european phase	Free format text: ORIGINAL CODE: 0009012
2003-05-21	AK	Designated contracting states	Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE TR
2003-05-21	AX	Request for extension of the european patent	Extension state: AL LT LV MK RO SI
2004-02-11	AKX	Designation fees paid	Designated state(s): GB
2004-03-18	REG	Reference to a national code	Ref country code: DE Ref legal event code: 8566
2004-08-13	STAA	Information on the status of an ep patent application or granted ep patent	Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN
2004-09-29	18D	Application deemed to be withdrawn	Effective date: 20031122

Publication	Publication Date	Title
EP2176248B1 (de)	2010-09-29	Neue antimikrobielle verbindungen, ihre synthese und ihre verwendung zur behandlung von säugetierinfektionen
EP2029583B1 (de)	2010-06-09	Neue benzothiazinonderivate und ihre verwendung als antibakterielle mittel
WO2012137224A1 (en)	2012-10-11	Coumarin compounds for the treatment of mycobacterial infections
EP2570413A1 (de)	2013-03-20	Benzothiazinon-Derivate als Wirkstoffe gegen Tuberkulose
US20080255166A1 (en)	2008-10-16	Dithiocarbamate derivatives and their use as antibacterial agents
RU2395508C1 (ru)	2010-07-27	Новые производные бензотиазинона и их применение в качестве антибактериальных средств
EP2181998B1 (de)	2012-09-19	Neues Benzothiazinon-Derivat und seine Verwendung als antibakterieller Wirkstoff
HK1142605A (en)	2010-12-10	New benzothiazinone derivative and its use as antibacterial agent